期刊文献+

药物体外转运模型及普萘洛尔异构体转运动力学研究 被引量:6

Enantioselective transport of R/S-propranolol in Caco-2 cell monolaysers
下载PDF
导出
摘要 目的:用近年来最具代表性的研究口服药物吸收机制的Caco-2细胞单层模型,研究盐酸普萘洛尔异构体的吸收及其吸收机制。方法:建立Caco-2细胞单层模型,研究不同浓度不同时间点该药物异构体的转运情况,通过柱前衍生化的RP—HPLC法检测盐酸普萘洛尔的异构体。结果:盐酸普萘洛尔吸收完全,主要为被动吸收,其异构体在Caco-2细胞模型上吸收无手性选择性。结论:本文建立了Caco-2细胞模型,并进行了完整性评价,表明Caco-2细胞模型完整性良好,将其用于手性药物盐酸普萘洛尔的吸收转运实验。同时还建立了柱前衍生化的RP-HPLC法,可以在20min内分离测定盐酸普萘洛尔异构体,方法操作简便、精密度好、结果准确可靠。 Objective:to study the absorption and absorption characteristics of isomer of propranolol hydrochloride in Caco-2cell monolayers model,which have taken as the most representative model to investigate the absorption mechanism of oral drug in recent years. Methods:Caco-2 cell monolayers model was set up to study transport of isomer of propranolol hydrochloride. RP-HPLC method was applied to analyze isomer of propranolol hydrochloride through precolumn derivatization. Results:Propranolol hydrochloride was absorbed completely,and was a passive diffusion mechanism. There was no chiral selectivity of transport and absorption of them across Caco-2 cell monolayers. Condusion:Caco-2 cell model was established and the cell integrity was evaluated. The integrity of Caco-2 cell was in good condition,which could be used to study the absorption and transport. RP-HPLC method was established to separated isomer of propranolol hydrochloride within 20 min by precolumn derivatization. The method is convenient, sensitive,accurate and suitable for the analysis of telbivudine.
出处 《重庆医科大学学报》 CAS CSCD 2008年第9期1038-1041,共4页 Journal of Chongqing Medical University
基金 重庆市自然科学基金资助项目(CSTC2005BB5227)
关键词 手性衍生化 HPLC 盐酸普萘洛尔 CACO-2细胞 GITC 表观通透系数 对映选择性 Chiral derivafization HPLC Propranolol hydrochloride Caco-2 cells GITC Papp Enantioselectivityl
  • 相关文献

参考文献12

  • 1Brown JR,Collett JH,Attwood D,et al.lntluence of moncaprinon the penn eability of a diacidic drug BTA-243 across Caco-2 cell monlayers and everted gut csc[J]. Int J Pharm, 2002; 245 ( 1-2 ) : 133- 142.
  • 2Artursson P.Cell cultures as models for drug absorption across the intestinalmucosa[J]. Crit.Riv.Ther.Drug Carrier Syst, 1991 ; 8(5 ) : 305- 330.
  • 3Tavelin S,Grasjo F,Tainpalensuu J,et al.Applieations fepithelial cell culture in studics of drug transport[J]. Methods MolBiol,2002; 188(8) :233-272.
  • 4沙先谊,方晓玲,吴云娟.9-硝基喜树碱在Caco-2细胞模型中的体外摄取、转运及外排动力学[J].药学学报,2004,39(10):839-843. 被引量:21
  • 5杨海涛,王广基.Caco-2单层细胞模型及其在药学中的应用[J].药学学报,2000,35(10):797-800. 被引量:58
  • 6Pigman EA,Blanchard J,Laird,ll H.E. et al. A study of cadmium transport pathways using the caco -2 cell model[J]. Toxicology and App lied Pharmacology, 1997; 142(2):243-247.
  • 7Lennernas H,Palm U,Fagerholm P,et aL Comparison between active and passive drug transport in human intestinal epithelial (Caco-2)cells in vitro and human jejunum in vivo[J]. International Journal of Phar maceutics, 1996; 127( 1 ) : 103-107.
  • 8Walgren RA,Karnaky KJ,Lindenrmayer GE,et al. Efflux of diet ary flavonoid guercetin 4-β-glucoside across human intestinal Caco-2 cell monolayers by apicalmultidrugresistance-associatedproten-2 [J]. JPharmcolExpTher, 2000; 294( 3 ) : 830.
  • 9Pham-Huy C,Sabui-Gnassi A,Saada V,et al. Mieroassay of propr anolol enantiomers and conjugates in human plasma and urine by high-performance liquid chromatography after chiral derivatization for Dharmacokinetic study[J].1 Pharm Rinmed Anal,1994:12(9):1189-1198.
  • 10Lennemal H,Palm K,Fagerholm U,et al.Comparison hetween active and passive drug ransport in human intestinal epithelial(Caco-2 )cells in vitro and human jeiunum in vivo[J]. Intemation Journal of Pharmac eutics, 1996; 127(85 ) : 103-107.

二级参考文献13

  • 1陈纪岳,胡明,朱彦平.药物从人小肠上皮细胞模型排放的动力学模型[J].上海医科大学学报,1996,23(4):247-251. 被引量:8
  • 2[1]Pantazis P, Earuj JA, Kozielski AJ, et al. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro [J]. Cancer Res, 1993,53(7) :1577 - 1582.
  • 3[2]Sands H, Mishra A, Stoeckler JD, et al. Preclinical activity of an iv formulation of rubitecan in IDD-PTM against human solid tumor xenografts [ J ]. Anticancer Drugs, 2002,13 (9): 965 - 975.
  • 4[3]Zhong DF, Li K, Xu JH, et al. Pharmacokinetics of 9-nitro-20 (S) -camptothecin in rats [ J ]. Acta Pharmacol Sin, 2003,24 (3) :256 - 262.
  • 5[4]Creemers GJ, Gervits CJH, Eckhardt J. Phase Ⅰ and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors [J].J Clin Oncol, 1997,15(3) :1087 - 1090.
  • 6[5]Chu XY, Suzuki H, Ueda K, et al. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines[J]. J Pharmacol Exp Ther , 1999,288(2) :735 -741.
  • 7[6]Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport[J]. Adv DrugDeliv Rev, 2001,46(1 -3):27 -43.
  • 8[7]Hu M, Chen J, Zhu Y, et al. Mechanism and kinetics of transcellular transport of a new lactam antibiotic loracarbef across an human intestinal epithelial model system (Caco-2) [J]. PharmRes, 1994,11(12):1405-1413.
  • 9[8]Monkkonen H, Tormalehto S, Asunmaa K, et al.Cellular uptake and metabolism of clodronate and its derivatives in Caco-2 cells: a possible correlation with bisphosphonate-induced gastrointestinal side-effects [J].Eur J Pharm Sci, 2003,19( 1 ) :23 -29.
  • 10[9]Warner DL, Burke TG. Simple and versatile highperformance liquid chromatographic method for the simultaneous quantity of the lactone and carboxylate forms of camptothecin anticancer drugs [ J ]. J Chromatogr B Biomed Appl, 1997,691 ( 1 ): 161 - 171.

共引文献74

同被引文献56

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部